Baker Bros. Advisors LP Allakos Inc. Transaction History

Baker Bros. Advisors LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$109.73 - $153.66 $1.23 Million - $1.72 Million	-11,200 Reduced 1.57%	703,050 $80.7 Million
Q4 2020 Feb 16, 2021	BUY	$79.58 - $152.45 $1.26 Million - $2.41 Million	15,781 Added 2.26%	714,250 $100 Million
Q3 2020 Nov 16, 2020	SELL	$66.43 - $90.99 $2.46 Million - $3.37 Million	-37,000 Reduced 5.03%	698,469 $56.9 Million
Q1 2020 May 15, 2020	BUY	$44.49 - $93.39 $17.6 Million - $37 Million	395,779 Added 116.51%	735,469 $32.7 Million
Q3 2019 Nov 14, 2019	BUY	$31.0 - $89.73 $10.5 Million - $30.5 Million	339,690 New	339,690 $26.7 Million

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $20.3M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.